$MSLE

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) completed enrollment for its Phase 2 BASECAMP trial of forazapadin for Duchenne muscular dystrophy. The trial, involving 18 sites globally, aims to assess safety, tolerability, and muscle force improvement. Satellos plans to share topline data in Q1 2027, adjusting from earlier plans to compile a comprehensive dataset.

Satellos Bioscience (MSLE) received FDA clearance for forazapadin to treat facioscapulohumeral muscular dystrophy (FSHD). The company plans a Phase 2 study in Q4 2026, with FSHD Canada Foundation providing up to $5M in funding. Forazapadin is also in Phase 2 trials for Duchenne muscular dystrophy (DMD).

Satellos Bioscience (MSLE) announced the WHO assigned the INN forazapadin to its lead drug candidate, SAT-3247, for treating DMD and other muscle diseases. The company expects to complete enrollment in the BASECAMP Phase 2 study by Q3 2026 and release data in Q4. It also plans to start a Phase 2 trial for FSHD by year-end. The stock closed at $9.18, up 2.00%.

A healthcare sector roundup highlights biotech stock moves. Zhongchao (ZCMD) rose about 192% after a 1-for-3 reverse split for Nasdaq compliance. Lakewood-Amedex (LABT) gained about 83% on positive Nu-3 Phase 2-ready updates. Arrowhead (ARWR) jumped about 19% after SHASTA-3/4 topline results for Plozasiran. Other gainers included MSLE, DRIO, and LBRX.

Satellos Bioscience (NASDAQ:MSLE) reported early results for SAT-3247 in its TRAILHEAD adult DMD study. In four participants, biceps brachii muscle fat fraction improved 3.7 points (49.7% to 46.0%) by day 140, with TE99c rising about 34% and creatine kinase down 38%. BASECAMP readout is expected in Q4.

Satellos Bioscience (NASDAQ: MSLE, TSX: MSCL) reported six-month interim TRAILHEAD data for SAT-3247 in four adults with Duchenne muscular dystrophy. Mean muscle fat fraction fell 3.7% (49.7% to 46.0%), TE99C effort rose about 34% (16.1 to 21.6 J/kg), CK fell 38% (2130 to 1315 u/l), and safety was favorable. A call is scheduled July 8.

Investment bank Leerink Partners has initiated coverage on Satellos Bioscience Inc. (MSLE) with an "Outperform" rating and a $20 target price. This positive outlook by analysts highlights the biotechnology company's innovative technology platform. The report aims to provide professional research references for investors interested in Satellos Bioscience.